Corsera Health secured an $80 million Series B to advance a novel bispecific antibody designed to simultaneously target two immune checkpoints in solid tumors. The Boston-based biotech is developing COR-101, a first-in-class bispecific antibody that inhibits both TIGIT and a second undisclosed checkpoint receptor, aiming to overcome resistance seen with single-agent immunotherapies. The company's pipeline also includes COR-202, a preclinical antibody-drug conjugate for a validated oncology target. The new capital is earmarked specifically to fund a Phase 2 trial of COR-101 in non-small cell lung cancer patients who have progressed on PD-1/L1 inhibitors, with data expected in 2027. While the investor syndicate was not disclosed, the round's size suggests backing from specialist life science VCs familiar with the high-risk, high-reward oncology bispecific space. Bispecific antibodies continue to attract major venture investment as the field moves beyond hematology into more challenging solid tumors.